Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Palliative Care × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 24 Gastrointestinal 22 Other hematologic neoplasm 19 Tumor-Agnostic 14 Thoracic 11 Gynecologic 11 Lymphoid 10 Genitourinary 10 Other solid neoplasm 6 CNS 6 Plasma cell 5 Head & Neck 5 Sarcoma 4 Myeloid 3 Dermatologic 3 Endocrine 2 Other 1 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48 Everolimus 40 Magnetic Resonance Spectroscopy 21 lanreotide 17 Temozolomide 17 gallium Ga 68 dotatate 15 Octreotide 15 pembrolizumab 13 Nivolumab 13 surufatinib 12 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sunitinib 10 pasireotide 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 Lutetium-177 9 3-Iodobenzylguanidine 9 Ga(III)-DOTATOC 8 Carboplatin 8 telotristat ethyl 6 copper dotatate CU-64 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Ipilimumab 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01849523 2024-05-06

WIN

University Medical Center Groningen

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡